Regeneron cannot immediately block U.S. sales of rival Amgen's proposed copy of its blockbuster eye-care drug Eylea, a ...

Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for ...

Adds Wells Fargo analyst comment. Regeneron Pharmaceuticals (NASDAQ:REGN) quickly dropped 3.5% after a judge denied the ...

Shares of Regeneron fell 5% yesterday after the company’s effort to block Amgen from launching a biosimilar version of its ...

Regeneron (REGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...

A U.S. judge ruled that Regeneron Pharmaceuticals cannot immediately block U.S. sales of a proposed copy of its blockbuster ...

Regeneron stock toppled Monday after a judge unexpectedly rejected a request that would have prevented Amgen from launching an Eylea copycat.

Regeneron sued Amgen in January, alleging that it was developing a biosimilar that violated key patent protections for Eylea.

Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that ...

A federal judge rejected Regeneron's request for a preliminary injunction against Amgen in its lawsuit for Eylea's biosimilar ...

Regeneron Pharmaceuticals is a leading biotech firm with a strong portfolio. Click here to know what justifies a Buy rating ...

Barclays analyst Carter Gould maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,220.00.